Success Stories: Success Stories: Cardiovascular Researcher from China Secures NIW Approval for Groundbreaking Medical Discoveries

Client’s Testimonial:

“Thank you very much for your great help throughout the whole process! I am happy to write a review on the website.”

On May 1^st, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Doctor/ Cardiologist in the Field of Medicine (Approval Notice).

General Field: Medicine

Position at the Time of Case Filing: Doctor/ Cardiologist

Country of Origin: China

Country of Residence at the Time of Filing: China

Approval Notice Date: May 1^st, 2025

Processing Time: 10 months, 21 days

Case Summary:

We are delighted to share the approval of a National Interest Waiver (NIW) petition for a distinguished researcher in the field of cardiovascular medicine. The petition, filed on June 10, 2024, and approved on May 1, 2025, highlights our client’s remarkable achievements and the clear benefit her work offers to the United States.

Our client is an accomplished medical scientist whose work focuses on the molecular mechanisms underlying cardiovascular disease (CVD). Her most notable contributions include studies on the gut microbiota’s role in hypertension, the STING pathway in aortic dissection, and the development of gene therapies for heart regeneration. Through her innovative research, she has helped uncover new avenues for therapeutic intervention and significantly deepened the medical community’s understanding of complex cardiovascular conditions.

She is currently employed in a U.S. medical research setting, where she continues her investigations into regenerative therapies for heart disease. Her continued research is aimed at identifying novel molecular targets that can dramatically improve patient outcomes.

To support the petition, we documented her outstanding qualifications and extensive scientific contributions:

★ Publications: 24 peer-reviewed journal articles and 4 scientific abstracts.
★ Citations: Her work has been cited 2,266 times, placing her among the top 1% most-cited authors in medicine in the last decade.
★ Review Service: She has completed at least 19 peer reviews for top-ranked scientific journals in cardiology and internal medicine.
★ Funding: Her research has received support from prestigious organizations, including the NIH, the National Natural Science Foundation, and multiple international medical research foundations.

In the petition, we showcased how her research directly contributes to U.S. interests in health care innovation, disease prevention, and long-term economic productivity through better treatment options. A key supporting letter from an independent expert stated:

“Her pioneering studies on gut microbiota and cardiovascular disease have provided novel insights into disease etiology and treatment that are directly informing ongoing research in leading institutions worldwide.”

We further emphasized how her work has appeared in the highest-impact journals in the field, including Circulation, Science Translational Medicine, and JAMA Surgery, and how it continues to inspire researchers globally, from Europe to Asia to North America.

Through a meticulously prepared petition and a robust body of evidence, we demonstrated that she meets the legal standards for an NIW by showing her work is of substantial merit and national importance, and that she is exceptionally well-positioned to continue contributing meaningfully in the United States.

We are proud to have played a part in her success and wish her continued impact as she advances cardiovascular health research and innovation.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.